Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Daniel Skovronsky"


9 mentions found


“I was depressed, severely depressed for that whole time.”Five months earlier, in October 2022, Bentley had started taking Mounjaro for weight loss. Ozempic uses the active ingredient semaglutide, and Wegovy is the version approved for weight loss. Mounjaro uses tirzepatide, which also targets a second hormone called GIP, and Zepbound is its brand name for weight loss. Safety in pregnancyEven as GLP-1 medicines may increase fertility, little is known about their safety during pregnancy. “It’s kind of like heart failure or sleep apnea,” he said, referring to conditions for which GLP-1 drugs have recently shown positive results.
Persons: CNN — Catera Bentley, Bentley, , , ” Bentley, she’d, , , ’ Bentley, Jody Dushay, Dushay, Catera Bentley, Ivy, Daniel Drucker, ” Drucker, they’re, Drucker, Eli Lilly, ” Dushay, haven’t, That’s, Anuja Dokras, Dokras, Melanie Cree, Cree, PCOS, aren’t, Eli Lilly’s, Daniel Skovronsky, ” Skovronsky, Dr, Sanjay Gupta, it’s, Mounjaro Organizations: CNN, Beth Israel Deaconess Medical Center, Harvard Medical School, University of, Mount Sinai, Novo Nordisk, Zepbound, US Centers for Disease Control, University of Pennsylvania, PCOS, Children’s Hospital, National Institutes of Health, CNN Health Locations: Steele , Alabama, Mount, United States, Children’s Hospital Colorado, , Colorado
Can a Big Pharma Ever Be Worth $1 Trillion?
  + stars: | 2023-11-29 | by ( David Wainer | ) www.wsj.com   time to read: 1 min
Daniel Skovronsky, chief scientific and medical officer at Eli Lilly, pushed the company to move more quickly and focus more on science. Photo: Maddie McGarvey for The Wall Street JournalThere are five tech companies valued at over $1 trillion. In healthcare, the closest contender is Eli Lilly . This year it became the first big pharmaceutical to surpass a market capitalization of $500 billion thanks to the popularity of its obesity and diabetes medications and, to a lesser extent, its experimental Alzheimer’s drug. But hanging over Lilly and rival Novo Nordisk is a reality that puts the brakes on big pharma’s ascent: the patent cliff.
Persons: Daniel Skovronsky, Eli Lilly, Maddie McGarvey, Lilly Organizations: Wall, Novo Nordisk
(Reuters) -Eli Lilly and Co on Wednesday appointed a new chief for its diabetes and obesity unit in a string of leadership changes ahead of a key regulatory decision on the use of its potential blockbuster drug Mounjaro as a weight-loss treatment. Slideshow ( 2 images )Mounjaro, chemically known as tirzepatide, is already being prescribed by doctors off-label as an obesity treatment. In his new role, Jonsson will oversee Lilly’s launched products and late-stage development of diabetes and obesity treatments, including tirzepatide and other candidates such as its next-generation obesity drug retatrutide and obesity pill orforglipron. Mason, who has also spent more than three decades with Lilly, oversaw the late-stage development and the launch of Mounjaro. The diabetes drug, which clocked in sales of $979.7 million in the latest quarter, belongs to a class of drugs known as GLP-1s that stimulate insulin production.
Persons: Eli Lilly, Patrik Jonsson, Lilly USA, Mike Mason, Jonsson, Lilly’s, Mason, Lilly, Daniel Skovronsky Organizations: Reuters Locations: Sweden, Scandinavia, Italy, Japan, Jonsson
Treating Alzheimer’s patients as early as possible — when symptoms and brain pathology are mildest — provides a better chance of slowing cognitive decline, a large study of an experimental Alzheimer’s drug presented Monday suggests. The study of 1,736 patients reported that the drug, donanemab, made by Eli Lilly, can modestly slow the progression of memory and thinking problems in early stages of Alzheimer’s, and that the slowing was greatest for early-stage patients when they had less of a protein that creates tangles in the brain. For people at that earlier stage, donanemab appeared to slow decline in memory and thinking by about four and a half to seven and a half months over an 18-month period compared with those taking a placebo, according to the study, published in the journal JAMA. Among people with less of the protein, called tau, slowing was most pronounced in those younger than 75 and those who did not yet have Alzheimer’s but had a pre-Alzheimer’s condition called mild cognitive impairment, according to data presented Monday at the Alzheimer’s Association International Conference in Amsterdam. “The earlier you can get in there, the more you can impact it before they’ve already declined and they’re on this fast slope,” Dr. Daniel Skovronsky, Eli Lilly’s chief medical and scientific officer, said in an interview.
Persons: Eli Lilly, donanemab, , they’ve, Dr, Daniel Skovronsky, Eli Lilly’s Organizations: Alzheimer’s Association International Locations: Amsterdam
It was shown in May and in fuller Phase 3 clinical trial results released at the Alzheimer’s Association International Conference on Monday to delay the disease’s progression. More than 6 million Americans are estimated to have Alzheimer’s disease, with about 1 million estimated to be in the early symptomatic stages where these drugs have shown benefit. Both Leqembi and donanemab work by clearing buildups of a protein in the brain called amyloid, a hallmark of Alzheimer’s. It’s been a hypothesis that treating Alzheimer’s earlier with amyloid-clearing drugs would yield better results; Skovronsky said the donanemab trial bore that out. “We could look at people who had mild cognitive impairment, MCI, which is the earliest stage, versus mild Alzheimer’s versus moderate Alzheimer’s,” Skovronsky explained.
Persons: Leqembi, Eli Lilly’s donanemab, Lilly, “ Donanemab, Jennifer Manly, Kacie, , Dr, Gil Rabinovici, Renaud La Joie, Daniel Skovronsky, , Skovronsky, ” Skovronsky, It’s, Eric Widera, Sharon Brangman, University of Wisconsin’s Dr, Nathaniel Chin, Donanemab, Lilly hasn’t, Lawrence Honig, Honig, White, Sanjay Gupta, Deters, ” Lilly, it’s “, it’s, there’s, Joe Montminy Organizations: CNN, Alzheimer’s Association, Food and Drug Administration, American Medical Association, Columbia University Irving Medical Center, University of California, MCI, SUNY, University of Wisconsin’s, Leqembi, FDA, donanemab, CNN Health, ” Manly Locations: Los Angeles,
FDA Commissioner Dr. Robert Califf speaks at an event celebrating hearing aids being available over the counter at a Walgreens in Washington, D.C., Oct. 19, 2022. Food and Drug Commissioner Dr. Robert Califf praised results Eli Lilly announced Wednesday that a clinical trial showed its Alzheimer's treatment donanemab slowed progression of the disease. "We have to look at the data when it comes in before making a judgment, but if the data look as good as the press release — this is really, really exciting," the commissioner said. The antibody treatment also carries risks of brain swelling and bleeding that can be severe and even fatal in rare circumstances. Full-time civil servants who are prohibited from having financial conflicts of interest make those decisions, the commissioner said.
The Alzheimer's treatment donanemab, which is made by Eli Lilly , significantly slowed progression of the mind-robbing disease, according to clinical trial data released Wednesday by the company. Patients who took donanemab were 39% less likely to progress to the next stage of the disease during the study, according to the trial results. Dr. Daniel Skovronsky, Lilly's chief scientific and medical officer, said donanemab demonstrated the highest level of efficacy of any Alzheimer's treatment in a clinical trial. In a separate measure, patients who received donanemab showed 40% less decline in their ability to conduct daily activities at 18 months. "These are the strongest phase 3 data for an Alzheimer's treatment to date.
Lilly manufactures tirzepatide, which is sold under the brand name Mounjaro as a type 2 diabetes treatment. It's the chronic nature of obesity that will make these drugs so profitable, analysts have said. Huynh increased his target due to higher expectations for Mounjaro sales this year. Huynh boosted his prediction for the drug's sales this year to $3.7 billion from an prior estimate of $2.7 billion. "$48 billion is a monster number," Holz said, referring to an annual sales estimate that Bank of America has floated for future Mounjaro sales.
But amid some positive news, companies focused on Alzheimer's have said they've received an influx of investor interest. In trials, Leqembi was found to slow the rate of cognitive decline by 27% in Alzheimer's patients over 18 months. Eli Lilly's drug donanemab is expected to have data soon but just faced a setback from the FDAEli Lilly's donanemab is the focus of a late-stage trial. In the first half of this year, Eli Lilly is expected to release data for its Alzheimer's drug donanemab, which is being tested in a late-stage trial. Getty ImagesAduhelm, the first Alzheimer's drug to be approved in 18 years, was OK'd by the FDA in 2021 but has faced controversy.
Total: 9